What do systematic reviews say?

BBV152 – Bharat Biotech vs placebo

BBV152 – Bharat Biotech leads to lower serious adverse eventsi compared with placebo (high certainty).

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  RR 0.65 [0.43, 0.97]
  1 study · 25928 participants
  High

BBV152 – Bharat Biotech vs placebo

BBV152 – Bharat Biotech showed no clear difference in local reactogenicity eventsg compared with placebo (high certainty).

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  RR 1.08 [0.95, 1.24]
  2 studies · 25750 participants
  High

NVX‐CoV2373 – Novavax vs placebo

The review found no eligible studies for this question.

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

NVX‐CoV2373 – Novavax vs placebo

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 42175 participants
  Moderate

mRNA‐1273 – ModernaTX vs placebo

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 31632 participants
  Moderate

NVX‐CoV2373 – Novavax vs placebo

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 25452 participants
  Moderate

NVX‐CoV2373 – Novavax vs placebo

NVX‐CoV2373 – Novavax showed no clear difference in all‐cause mortalityh compared with placebo (low certainty).

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  RR 0.9 [0.3, 2.68]
  1 study · 29582 participants
  Low

NVX‐CoV2373 – Novavax vs placebo

NVX‐CoV2373 – Novavax leads to higher systemic reactogenicity eventsj compared with placebo (high certainty).

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  RR 1.21 [1.17, 1.25]
  3 studies · 31063 participants
  High

NVX‐CoV2373 – Novavax vs placebo

NVX‐CoV2373 – Novavax probably leads to higher any adverse eventm compared with placebo (moderate certainty).

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  RR 1.15 [1.05, 1.26]
  5 studies · 46231 participants
  Moderate

NVX‐CoV2373 – Novavax vs placebo

NVX‐CoV2373 – Novavax showed no clear difference in serious adverse eventsm compared with placebo (low certainty).

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  RR 0.92 [0.74, 1.14]
  4 studies · 38802 participants
  Low

NVX‐CoV2373 – Novavax vs placebo

NVX‐CoV2373 – Novavax leads to higher local reactogenicity eventsj compared with placebo (high certainty).

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  RR 2.78 [1.99, 3.88]
  3 studies · 31063 participants
  High

FINLAY‐FR‐2 – Instituto Finlay de Vacunas vs placebo

The review found no eligible studies for this question.

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

FINLAY‐FR‐2 – Instituto Finlay de Vacunas vs placebo

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 28674 participants
  Moderate

FINLAY‐FR‐2 – Instituto Finlay de Vacunas vs placebo

The review found no eligible studies for this question.

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

FINLAY‐FR‐2 – Instituto Finlay de Vacunas vs placebo

FINLAY‐FR‐2 – Instituto Finlay de Vacunas probably leads to lower all‐cause mortalitye compared with placebo (moderate certainty).

• Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
  RR 0.37 [0.17, 0.8]
  1 study · 28674 participants
  Moderate

Corticosteroids vs placebo or no treatment

Neonatal and child outcomes: corticosteroids leads to lower neonatal death (infants born with signs of life who die within the… compared with placebo or no treatment (high certainty).

• Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth 2020 · Cochrane Headline outcomes only
  RR 0.78 [0.7, 0.87]
  Studies not reported
  High

Corticosteroids vs placebo or no treatment

Neonatal and child outcomes: corticosteroids leads to lower respiratory distress syndrome№ of participants: 11,183(26 RCTs) compared with placebo or no treatment (high certainty).

• Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth 2020 · Cochrane Headline outcomes only
  RR 0.71 [0.65, 0.78]
  Studies not reported
  High

Corticosteroids vs placebo or no treatment

Neonatal and child outcomes: corticosteroids probably leads to lower intraventricular haemorrhage (IVH)№ of participants: 8475(12 RCTs) compared with placebo or no treatment (moderate certainty).

• Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth 2020 · Cochrane Headline outcomes only
  RR 0.58 [0.45, 0.75]
  Studies not reported
  Moderate

Corticosteroids vs placebo or no treatment

• Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  High

Corticosteroids vs placebo or no treatment

Neonatal and child outcomes: corticosteroids probably leads to lower developmental delay in childhood№ of participants: 600 (3 RCTs). Age… compared with placebo or no treatment (moderate certainty).

• Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth 2020 · Cochrane Headline outcomes only
  RR 0.51 [0.27, 0.97]
  Studies not reported
  Moderate